gliptin monotherapy [4] [5] [6] .
The 5-hydroxytryptaine (5-HT) receptor subtypes have been identified as 5-HT 1 to 5-HT 7 . The 5-HT 4 receptor is abundant in the stomach and intestine [7] [8] [9] . A 5-HT 4 receptor agonist accelerated gastric emptying and motility [10] . Mosapride citrate, a selective agonist of the 5-HT 4 receptor, is typically used to treat heartburn, nausea, and vomiting associated with chronic gastritis (5 mg, three times a day) or to prepare for a barium enema X-ray examination before (20 mg) and after (20 mg) the oral intake of gastrointestinal lavage solution. Mosapride has no dopamine D 2 receptor antagonist activity, unlike other gastrokinetic agents such as metoclopramide [11] . Mosapride citrate reportedly improves glycemic control in patients with type 2 diabetes [12] and in patients with gastropathy arising from diabetes [13] . By contrast, cisapride, which is another selective agonist of the 5-HT 4 receptor but is presently prohibited because of its effect on the QT interval, has no effect on glycemic control [14, MA, USA) at SRL, Inc. (Tokyo, Japan). The plasma total GLP-1 levels were measured using an ELISA kit (Millipore Corporation, MA, USA) at our laboratory. The plasma active GLP-1 level was measured using a direct method according to our recent report [17] . We measured the total GIP level in this study because we could not obtain a commercially available kit capable of measuring active GIP accurately.
Statistical analysis
The data were expressed as the means ± SE. The analyses of the time profiles were performed using a twoway analysis of variance (ANOVA) with Bonferronitype multiple comparisons. The area under the curve (AUC) from after the start of the meal until 180 min was calculated using the trapezoid method, and the results were analyzed using a paired t-test.
Results
The time profiles and the AUCs for the plasma glucose levels are shown in Fig. 1 . The plasma glucose levels at 120 and 180 min after the start of the meal were significantly lower in the mosapride citrate-treated group than in the control group (Fig. 1A) . As a result, the AUC of the plasma glucose levels was smaller in the mosapride citrate-treated group than in the control group ( Table 2) .
The serum insulin levels at 60 and 120 min after treatment with mosapride citrate tended to be elevated, but the differences were not statistically significant ( Fig.  2A) . No significant differences in the AUCs for serum insulin were observed between the two groups (Table 2) . Also, no significant differences in the time profiles or the AUCs for the plasma glucagon levels were observed between the two groups ( Fig. 3A and Table 2 ).
The plasma active GLP-1 levels at 60 and 120 min after the meal were significantly higher in the mosapride citrate-treated group than in the control group (Fig. 4A) . As a result, the AUC of the plasma active GLP-1 levels was significantly larger in the mosapride citrate-treated group than in the control group ( Table 2 ). The plasma 15]. Thus, the mechanisms responsible for the effect of mosapride citrate on the amelioration of hyperglycemia remain unknown. Metoclopramide, which antagonizes the dopamine D 2 and 5-HT 3 receptors and stimulates 5-HT 4 receptors, reportedly increases GLP-1 and GIP release after the intraduodenal infusion of glucose [16] . As mosapride citrate activates the motility of the gastrointestinal tract, we hypothesized that mosapride citrate might also affect incretin secretion. Therefore, we examined the effect of the administration of mosapride on the plasma glucose, serum insulin, plasma glucagon, and plasma incretin levels in men with normal glucose tolerance (NGT) or impaired glucose tolerance (IGT) to exclude gastropathy.
Materials and Methods

Subjects and measurements
After obtaining approval from the Institutional Ethics Review Committee of Yokohama City University, 12 men (3 IGT men and 9 NGT men) were enrolled, as shown in Table 1 . Informed consent was obtained from each of the subjects prior to the start of the study. The protocol was registered in the UMIN Clinical Trial Registry as UMIN000007292. This trial was performed over the course of two days in each subject (Day 1: no mosapride, Day 2: mosapride alone [20 mg] administered 2 hours before breakfast). These two trials were conducted within 2 weeks for each subject. Three men enrolled in this study received the same standard breakfast on day 1 and day 2 (849 Kcal; protein: 25.3 grams; fat: 27.5 grams; carbohydrate: 125 grams), and nine men received a different standard breakfast on day 1 and day 2 (674 Kcal; protein: 20.4 grams; fat: 22.4 grams; carbohydrate: 97.8 grams).
Blood samples were collected before the start of breakfast and at 60, 120, and 180 min after the start of breakfast. The plasma glucose, serum insulin, plasma glucagon, plasma active and total GLP-1, and plasma total GIP levels were measured. The plasma active GLP-1 and plasma total GIP levels were measured using an ELISA kit (Millipore Corporation, 
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tration of mosapride in all the subjects (Fig. 4B) . The AUCs for the plasma total GLP-1 levels were increased in 6 subjects whose insulin levels were also increased after mosapride administration (Fig. 5B) . The values were also increased in all 5 subjects whose insulin levels were not increased after mosapride administration (Fig. 5B) . Accordingly, differences in the active and total GLP-1 levels were not seen between the subjects with and those without an increase in their insulin levels after mosapride administration.
total GLP-1 levels at 60 and 180 min after the start of the meal in the mosapride citrate-treated group were significantly higher than those in the control group (Fig.  5A) . As a result, the AUC of the plasma total GLP-1 level was significantly larger in the mosapride citratetreated group than in the control group ( Table 2) . The AUCs for serum insulin were increased by the administration of mosapride in 7 subjects and decreased in 5 subjects (Fig. 2B) . The AUCs for the plasma active GLP-1 levels were increased after the adminis- 
of the present study, mosapride citrate appears to exert an antidiabetic effect by increasing GLP-1 secretion.
Mosapride citrate reportedly has beneficial effects in patients with diabetes. Ueno et al. reported that the administration of mosapride citrate for one week significantly improved the glucose responses as evaluated using an intravenous glucose test [12] . They also reported that the administration of mosapride citrate significantly increased the number of and the tyrosine autophosphorylation of insulin receptors as well as the No significant differences in the time profiles and the AUCs for the plasma total GIP levels were observed between the two groups ( Fig. 6A and Table 2 ).
Discussion
The most important finding in this study is that the administration of mosapride citrate increased the AUC of the plasma active GLP-1 level and decreased the AUC of the plasma glucose level. Based on the results The control group is shown as the dotted line, and the mosapride group is shown as the solid line. The data are presented as the mean ± SE. **P < 0.01 and ***P < 0.001 vs. control group. B: AUCs of the plasma total GLP-1 levels from the start of breakfast until 180 min after breakfast for each subject before and after the administration of mosapride citrate. The AUCs of the 3 IGT men are shown as the dotted lines, and the AUCs of the 9 NGT men are shown as the solid lines. 
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to elucidate the mechanism responsible for the increase in GLP-1 secretion and flow in the small intestine. Given the fact that diabetes develops when the insulin secretion by beta cells is insufficient to compensate for insulin resistance [22, 23] and GLP-1 reportedly inhibits apoptosis in humans, the increase in the GLP-1 concentration may be important for improving beta cell function [24] . In addition, the increase in GLP-1 may protect against obesity because of the anti-obesity effect GLP-1 [25] [26] [27] [28] .
The standard dose for chronic gastritis is 5 mg three times daily (15 mg/day), while 20 mg of mosapride citrate is clinically used to prepare for a barium enema X-ray examination. We used 20 mg of mosapride in this study because the single administration of 5 mg of mosapride is considered to have a relatively weak effect on improving metabolic parameters during the meal tolerance test. We plan to evaluate the effect of the single administration of mosapride (5 mg dose) on glucose metabolism in the future.
In conclusion, the administration of mosapride citrate increased GLP-1 secretion and decreased the AUC of the plasma glucose level. In the future, we would like to evaluate the effectiveness of mosapride citrate on incretin levels in patients with type 2 diabetes.
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No potential conflicts of interest relevant to this article were present. glucose infusion rate using a hyperinsulinemic-normoglycemic clamp study. Nam et al. reported that mosapride citrate increased the recruitment of glucose transporters from the intracellular pool in skeletal muscle [18] . The administration of mosapride once at night decreased the HOMA-R index when it was measured the following morning in patients with type 2 diabetes [19] . These studies suggest that mosapride citrate improves insulin sensitivity; however, the mechanisms by which mosapride citrate improves diabetes have not been fully elucidated.
The increases in the plasma total and active GLP-1 levels after the administration of mosapride citrate suggested that mosapride citrate increases GLP-1 secretion, rather than inhibiting DPP-4 activity. The AUC of the plasma glucose levels was significantly lower in the mosapride citrate group than in the control group. The serum insulin levels tended to be elevated after treatment with mosapride citrate, but the difference was not statistically significant. These tendencies were compatible with the elevation in GLP-1 secretion after the administration of mosapride citrate. GLP-1 is known to suppress glucagon secretion; however, the plasma glucagon levels were similar in the two groups in this study.
The GLP-1 and GIP levels after a meal test were reportedly elevated after a sleeve gastrectomy [20] . The GLP-1 and GIP levels peaked at 30 min after glucose ingestion, and these levels at 30 min were significantly higher in patients that had undergone a gastrectomy than in control subjects [21] . Since mosapride citrate is a gastrokinetic agent, a larger amount of mixed food likely enters the small intestine after treatment. The glucose absorption in the upper portion of the small intestine might not be altered because of the increased movement and flow in the small intestine induced by mosapride citrate, despite the presence of a larger amount of mixed food from the stomach. As a result, this situation might lead to an increase in glucose absorption and GLP-1 secretion in the lower portion of the small intestine. Further studies are needed
